Navigation

Acute coronary syndromes - ticagrelor

Ticagrelor for the treatment of acute coronary syndromes (ACS)

Status: History
Expected date of issue: October 2011
Referral date: April 2009
Process: STA
Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Raisa Sidhu
Communications manager: Phil Ranson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 November 2010
1st appraisal committee meeting: 02 June 2011
2nd appraisal committee meeting 04 August 2011
Top


 

Consultees and commentators

Consultees

 

Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • AstraZeneca (ticagelor)

Patient/carer groups     

  • Action Heart
  • Heart Care Partnership (UK)
  • HEART UK
  • South Asian Health Foundation

Professional groups

  • British Cardiovascular Intervention Society (BCIS)
  • British Cardiovascular Society
  • British Heart Foundation
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Bradford and Airedale
  • Oxfordshire PCT
  • Welsh Government Assembly

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Bristol-Myers Squibb (clopidogrel)
  • Daiichi Sankyo (prasugrel)
  • Eli Lilly (prasugrel)
  • Sanofi-Aventis (clopidogrel)

Relevant research groups

  • British Society for Cardiovascular Research

Evidence Review Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Coordinating Centre for Health Technology Assessment

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
14 August 2009 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid June 2010. The deadline for submissions is expected in approximately mid August 2010.
24 December 2009 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid September 2010. The deadline for submissions is expected in approximately mid November 2010.
24 January 2011

Due to resource constraints and efficiency scheduling requirements for the current work programme, NICE has had to decide to re-schedule the first Appraisal Committee meeting for a number of the technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

The appraisal of ticagrelor for the treatment of acute coronary syndrome is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 2 June 2011.  The second committee meeting (if required) will also be rescheduled.

Please note that guidance from the Department of Health to NHS bodies on best practice  on funding where no NICE guidance has been published for a particular product can be found in ‘Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance’ (Department of Health, December 2006).

Top


 

Key documents

This page was last updated: 26 October 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.